3 Things US imposes more tariffs, labourers held captive, and Tamil Nadu stampede
11 snips
Sep 29, 2025 Ravi Dutta Misra, a journalist from The Indian Express specializing in trade policy, discusses the implications of new US tariffs on India's pharma sector, highlighting potential setbacks for R&D. Shubham Tigga, another reporter for The Indian Express focusing on labor issues, shares a gripping account of 13 Jharkhand workers lured by false promises and trapped in dangerous conditions. Their harrowing rescue sheds light on the grim reality of migrant worker exploitation in India, coinciding with a tragic stampede during a political rally in Tamil Nadu.
AI Snips
Chapters
Transcript
Episode notes
Tariffs Threaten India's Move Up The Pharma Chain
- The US 100% tariff on patented drugs won't immediately hit India's generic-dominant exports but will weaken incentives to move into patented drugs.
- Ravi Dutt Misra warns this could slow India's shift up the pharmaceutical value chain and R&D investment.
Section 232 Expands US Tariff Levers
- Expansion of Section 232 lets the US impose sectoral tariffs on national security grounds with little judicial review.
- Misra notes India risks enduring sector tariffs even if reciprocal tariffs are overturned in US courts.
Oil Issue Looms Over Trade Talks
- Trade talks with the US are progressing but oil imports remain a thorny sticking point in negotiations.
- Misra says a single tariff number will likely close talks rather than piecemeal product-by-product fixes.